At Medwisdom, we offer expert support for pharmaceutical manufacturers in aligning with the Revised Schedule M guidelines issued by CDSCO. The updated Schedule M, notified in 2024, emphasizes stricter Good Manufacturing Practices (GMP) to enhance the quality, safety, and efficacy of pharmaceutical products in India. It mandates significant improvements in facility design, HVAC systems, water quality, documentation, data integrity, and overall risk management practices.

Our regulatory specialists assist companies in understanding and implementing these changes through gap analysis, SOP development, staff training, and facility upgrades. We also support in preparing for inspections and audits by State FDAs and CDSCO.

Whether you're setting up a new manufacturing facility or upgrading existing ones, Medwisdom ensures full compliance with the Revised Schedule M to help you meet national and global quality standards, reduce regulatory risk, and build market credibility.

For more information, please visit our blog : https://medwisdom.in/revised-schedule-m/